Fushine(SZ:300497) Quan Jing Wang·2025-10-28 08:24Core Insights - Fuxiang Pharmaceutical reported a revenue of 769 million yuan for the first three quarters of 2025, highlighting its differentiated high-quality development path in the competitive chemical pharmaceutical sector [1] Group 1: R&D and Business Segments - The company is focusing on three core business areas: pharmaceutical manufacturing, new energy lithium battery materials, and synthetic biological microbial proteins, aiming to build a diversified strategic framework [2] - In pharmaceutical manufacturing, Fuxiang is enhancing product potential through green alternatives and process optimizations, leading to a continuous reduction in production costs and reinforcing its competitive position in the active pharmaceutical ingredient market [2] - The new energy segment has established a production capacity of 8,000 tons of vinyl carbonate (VC) and 3,700 tons of fluorinated ethylene carbonate (FEC), benefiting from a recovering market for electrolyte additives, with prices rising over 20% month-on-month [2] Group 2: Marketing and Market Expansion - Fuxiang is enhancing its market presence by deepening strategic partnerships with core customers and expanding into key international markets, thereby creating new growth opportunities [4] - The company has established the Weiran Alliance in Shanghai to facilitate the commercialization of its new protein products, attracting international brands as initial members [4] - Fuxiang is actively expanding into the East Asian market, having secured a patent in South Korea for its production technology, and is developing a subsidiary in Singapore to accelerate overseas market penetration [5] Group 3: Future Outlook - The company plans to continue strengthening its R&D investments, enhancing marketing networks, and fostering collaborative innovation with strategic partners to drive the application of microbial protein technology across various sectors [6]